Member Info for elrico

You may be surprised to learn that Boots isn't on the list or to know who it is.

https://lemminginvestor.substack.com/p/skinbiotherapeutics-plc-de2/comment/106778649

PG, please use the filter. I don't give the trolls the time; you don't need to, either. You're not telling anyone anything new.

Netcurtains, be blind to your calculations if you wish. My concern is no longer for you but for others. I appreciate the effort you've put into revisiting your original theory, particularly around Boots’ sales volumes, margins, and Croda’s royalty cut. However, it appears the revised interpretation is not only overcomplicating matters but is also built on a fundamentally flawed premise.

You’re, of course, entitled to stand by your view — whether that means dismissing my input or suggesting that even the CEO may be mistaken. Your argument contradicts the available facts. At some point, it becomes less a question of interpretation and more one of accuracy and stubourness.

I’ve offered my insights in good faith, not to score points but to help ensure prospective investors aren’t misled by misreading a relatively straightforward royalty structure. If that help is unwelcome, so be it — I’ll leave it there. I'm done. You can crack on.

Net, an overreliance on any LLM is dangerous. I could provide you with many examples during our testing, several of them as a method of avoiding using Google. To start, you need to provide any LLM with an accurate prompt. My understanding is that your premise is incorrect.

I can assure you, you're overcomplicating things. The method you're using to extract value is fundamentally flawed. I raised this with SA months ago. At this point, it's up to you — either take my word for it or don't. We're genuinely trying to help here. If you wish to hang from a cliff and slap away the friendly hand of assistance, that's your call.

You're correct. Biomimetic bond builder has nothing to do with SkinBiotix.

https://www.cosmeticsdesign-europe.com/Article/2024/02/22/New-skin-hair-technology-to-address-unsatisfied-demand/

netcurtains, i have to break it to you. pg is correct. royalties are paid on the weighted volume of the lysate sold by sederma, not the retail end. your *** packet is flawed. it doesn't matter what the retail value is; it's the weight sold. the end.

It may be a senile period. I can't locate anything specific to Clowning Street's roundtable.

I sent some info to SA as a request for input.

https://open.substack.com/chat/posts/f20c5893-1cf6-4b34-8c9b-783f88744189

Https://lemminginvestor.substack.com/p/skinbiotherapeutics-plc-de2

Cracked me up, Martin. Funny.

Ray, or is it Rodders? Are able to distinguish between public disclosures and actual insider information? I do wonder. What, precisely, was said that qualifies as insider knowledge? Do enlighten me—if only to satisfy my own curiosity!

You see, this is my job (yes, a real one)—to pose questions to Companies on behalf of investors. The aim, quaint though it may seem, is to bring some colour and clarity to announcements that, frankly, seemed designed to consfuse. Hence, the rather lively 9% tumble in early trading. Coincidence?

Now, you may not be leaping with gratitude for the efforts made, but do try to resist flinging around ill-informed accusations of insider dealing. It’s unbecoming—and, if I may say so, makes one sound rather like a wide-eyed retail investor freshly arrived on the scene, unsophisticated, one might allege.

Happy to assist, of course. Thank you ever so much, kind Sir.

Heads up. Croda PR is about to kick-in. https://open.substack.com/chat/posts/0ec2846a-c00f-4259-9a7a-8b7cb6ad27c0?target_reply_id=8b56d5ca-c7f8-4ed1-8682-7ebae130f86a&showTarget=true

Al, the following offers an overview without the in-depth information I was referring to. Easier to read. Before my groupies start screening, it is open source. https://open.substack.com/pub/lemminginvestor/p/skinbiotherapeutics-plc-095?r=kcv2o&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true

Al, I recall the quote from the investor meeting I held in Manchester—keep that in mind. A great deal has happened since then.

"The cosmetics industry is always in search of the next big breakthrough. When someone discovers it, suddenly, everyone wants a piece of it."

I believe he phrased it as "the next big thing," explaining that it would trigger a frenzy. His name escapes me, but he was well-known for developing shampoos and later became a consultant for some of the largest cosmetic companies.

There are more re-rates ahead than the two you've rightly identified. I suggest revisiting the editorial I wrote, which provides a comprehensive breakdown of the entire company—sector by sector—including partnerships and acquisitions.

Ashman gave me a very nice compliment after reading it. It meant I was bang on the money. If you can't find it, let me know.

PG, you are correct regarding my intervention and liaising with the FCA, which was instrumental in the taking down of Joseph Sheedy's financial website, which purported to have the support and a global "trojan army" of short-side clients set to target specific Companies. I had no hand in setting up the blog detailing his activities. Once the site was taken down, my work was complete.

I have moved on, even if he hasn't. I have a life, even if he hasn't. My site remains active; his has been taken down. I have members who appreciate what I/we do; he does not. We avoid investing in frauds; he ramps them. Well, one, SYME.

Thanks, Bazza. Unfortunately, history tends to repeat itself whenever we enter a quiet period—I inevitably become the target for the usual suspects. All of them are filtered. They can rationalise their conduct however they like, but the reality is simple: most people here are long-standing investors who are well aware of the history, including trying to cancel me and TW by vexatious complaints to the NOMAD and Company. I filter out baiters when it becomes personal, and they did get personal. I refuse to engage with them by defending myself, which isn’t productive for the board. The focus should be on all things SBTX, not on me.

I have no issue with anyone challenging my opinions or analysis—those who know me will be aware that I enjoy a good debate. Disagreements often lead to new insights, and avoiding an echo chamber is far more valuable than simply reinforcing existing views.

I have asked PG to refrain from engaging with anyone trying to bait me, and I do so publicly. I appreciate the good intentions. I think he now realises he's flogging a dead horse.

Let's get back to discussing the Company.

There is some truth to your reasoning, Al. During a 20-minute call with Tom Winnifrith, in which I shared our musing with our members, I explained that, in my view, the reason the share price was hovering around 20p at the time was that the market had yet to adjust its perspective.

What I meant was that confidence should be far higher, given that the success of the April launch rests entirely on Croda’s marketing team, along with the VIPs and, subsequently, the 500 other clients—rather than on SBTX itself.

Naturally, there remains some unease over the possibility of Macquarie offloading their warrants at any moment. While that is certainly a risk, it seems more likely that they would wait for increased liquidity, particularly if they are keeping an eye on the launch—which, one would hope, they are. Of course, they may well not care at all.

I am not hanging worrying about what the market thinks or what Maquarries does with its warrants. Today, I added 2x30k, 25k, and 17k buys. I view the current status as a valuable opportunity, maybe because I am not a trader and have a longer view.

PS. Can you, beautiful people, please leave me out of your love-in? It's embarrassing. Thank you.

Happy to help, Net.

Croda/Sederma will have conducted all the trials they needed to ahead of commercial green lights. Don't forget that 12 VIPs have been working closely with them for around two years. A further 500 clients were given access in November - This suggests (along with the first cheque) that they have been working on formulations ready for the official launch.

Net,

Gemini Ai, as with other LLM is prone to errors, just as your example is out of date. For example:

The additional clinical studies that Croda extended to investigate further beneficial properties of SkinBiotix were completed in September 2024. These studies yielded positive results, validating the efficacy and marketing claims of SkinBiotix for the cosmetics industry.

After successfully completing these studies, SkinBioTherapeutics and Croda have finalised the commercial terms for the partnership. The focus is now on commercialisation, with the formal launch of SkinBiotix as an active ingredient planned for In-Cosmetics Global in Amsterdam, April 2025.

While the statements about Croda's commitment to scientific validation and high hopes for the technology remain true, they are now more aligned with the commercialisation phase, such as "specific marketing claims" rather than ongoing clinical studies.

Net, that would be me.

Posted 9 March https://lemminginvestor.substack.com/p/investor-podcast-16 viewed over 600 times and downloaded 190 times. Apparently, I have a sexy voice...who knew!

Gents, PG and Oleric, can you leave me out of your debate, please? As I have discussed, SBTX is on a good mini-rally; this should be the focus.

I’ll admit, I haven’t clapped my eyes on Oleric’s comments in Donkey’s years. When I did, I’d just rope in my 8-year-old grandson to unravel them for me—turns out, they were bang on his level, proper primary school stuff! Even thought they were tedious, hence why I apply the filter.

Let's enjoy the rise and be grateful. It's about to get very interesting, far more than anything anyone can say about a fat little hobbit.

LSE will be getting its data from a 3rd party. It is always tricky when the bID/OFFER is as tight as it has been.